Jane Street
LCTX icon

Jane Street’s Lineage Cell Therapeutics LCTX Stock Holding History

Jane Street’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,100
Closed -$40.7K – 11832
2025
Q3 		$40.7K Sell
24,100
-39,800
-62% -$47.1K ﹤0.01% 10401
2025
Q2 		$58K Buy
+63,900
New +$37.9K ﹤0.01% 9142
2022
Q1 		– Sell
-44,900
Closed -$110K – 10700
2021
Q4 		$110K Buy
+44,900
New +$105K ﹤0.01% 9190
2016
Q4 		– Sell
-28,118
Closed -$96K – 4353
2016
Q3 		$96K Buy
+28,118
New +$77.7K ﹤0.01% 3852

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street's LCTX Position: Q1 2026 in Review

Jane Street reduced its Lineage Cell Therapeutics (LCTX) stake by 1.2% in Q1 2026, selling an estimated $19.5K and leaving 993,208 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #5548.

Jane Street first reported a position in LCTX in Q2 2014 and has held it in 40 quarters since. The position peaked at $1.68M in Q4 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Jane Street held 993,208 shares of Lineage Cell Therapeutics worth $1.57M as of Q1 2026.
  • Jane Street sold 11,586 Lineage Cell Therapeutics shares in Q1 2026, an estimated $19.5K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5548 holding.
  • Jane Street first reported a position in Lineage Cell Therapeutics in Q2 2014 and has held it in 40 quarters since.
  • Jane Street's Lineage Cell Therapeutics position peaked at $1.68M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.